Medicare's GLP-1 Bridge, By the Numbers

Eli Lilly's weight-loss drugs account for 70% of the Medicare patients who started a GLP-1 prescription since the federal government's new obesity-drug coverage program opened, chief executive David Ricks told CNBC on September 21, 2026. Ricks said about 700,000 seniors have begun GLP-1 treatment since the program launched on July 1, and roughly seven in ten of those new patients are on a Lilly medicine, led by the injectable Zepbound^[4].

What the Bridge program actually pays for

The program Ricks was describing is the Medicare GLP-1 Bridge, a temporary demonstration that runs from July 1, 2026 through December 31, 2027. Eligible Medicare Part D beneficiaries who enroll can fill a monthly supply of Zepbound, Foundayo, or injectable and oral Wegovy for a $50 copay. In exchange, the participating manufacturers supply the drug to Medicare at a negotiated net price of about $245 a month^[1]. The gap between what the patient pays and what the manufacturer is paid, roughly $195 a month per patient, is covered by Medicare^[3].

CMS is treating the Bridge as a stopgap, not a permanent benefit. Program materials describe it as a step toward a longer-term framework the agency calls the BALANCE Model, short for Better Approaches to Lifestyle and Nutrition for hEalth, which is meant to fold obesity treatment into a broader value-based payment structure once the Bridge demonstration winds down^[5].

Coverage is not automatic. To qualify, a beneficiary generally needs a body mass index of 35 or higher, or a BMI of 30 or higher plus a condition such as heart failure, uncontrolled hypertension, or kidney disease, or a BMI of 27 or higher plus a history of stroke, heart attack, prediabetes, or peripheral artery disease. A prescriber has to document the condition, submit a prior authorization, and confirm the patient has completed counseling on diet and physical activity before the pharmacy can fill the prescription at the reduced copay^[5].

The $50 copay applies only inside Medicare Part D prescription drug plans and Medicare Advantage plans that include drug coverage. A beneficiary enrolled only in Original Medicare, with no Part D plan, is not eligible regardless of BMI. Anyone who wants to confirm their own plan is participating, or wants the requirements explained without a news story in between, can call 1-800-MEDICARE or check Medicare.gov's Bridge program page directly^[5].

Why Lilly is capturing most of the new patients

Ricks attributed the imbalance mainly to Zepbound, which he said doctors are steering toward Medicare patients carrying the most body weight and the most weight-related health complications. Lilly's oral pill, Foundayo, is newer to the market: the FDA approved it on April 1, 2026 as a once-daily tablet that can be taken at any time of day without food or water restrictions, using the agency's National Priority Voucher program to shorten the review timeline^[2]. Ricks said Foundayo is now winning about a third of new Medicare patients who choose an oral GLP-1 over an injectable^[4], competing against Wegovy, Novo Nordisk's semaglutide brand, which is also on the Bridge formulary in both injectable and oral form. If new Medicare GLP-1 patients were splitting evenly between the two companies, Lilly's share of new starts would sit closer to half. Ricks's 70% figure means Medicare patients newly starting a GLP-1 are choosing a Lilly product at roughly twice the rate that even split would predict^[4].

The Medicare figures track a broader pattern in Lilly's business. Ricks put the company's share of the combined US obesity and diabetes drug market at around 61% as of the second quarter of 2026, against roughly 39% for Novo Nordisk, the maker of Wegovy and Ozempic. He called the Bridge program's early rollout "very market expansionary," meaning it is pulling in patients who had never taken a GLP-1 drug before rather than simply moving existing Ozempic or Wegovy patients onto Lilly's brands^[4].

What these numbers do not show

The 700,000 and 70% figures are Ricks's own count, given in a television interview, not a published CMS enrollment report. They also cover a small slice of the Medicare population: the program serves roughly 66 million people who are 65 or older or qualify through a disability, so 700,000 new starts is a fraction of one percent of the beneficiary pool^[4]. The Kaiser Family Foundation has estimated the Bridge program could cost Medicare anywhere from $1.3 billion to $10 billion over its 18-month run, a range wide enough that nobody, including CMS, appears to know yet how many more beneficiaries will enroll or how long they will stay on the drug^[3].

What happens after the Bridge expires is not settled either. The BALANCE Model that CMS points to as the next step has not been finalized, so nobody, including the drugmakers, knows yet whether a $50 copay will still exist in 2028 or whether beneficiaries who started on Zepbound, Foundayo, or Wegovy under the Bridge will face full price once the demonstration ends^[5].

The program is also explicitly temporary. Unless Congress or CMS extends it, the $50 copay and the negotiated net price expire on December 31, 2027, and coverage for GLP-1 weight-loss drugs reverts to whatever a beneficiary's individual Part D plan otherwise allows, which for many plans has meant no coverage at all^[1].

What this means if you are on Medicare

If you are on Medicare and considering asking your prescriber about the Bridge program, the practical questions are whether your Part D or Medicare Advantage plan is participating, whether you meet the BMI and health-history criteria CMS set, and whether your prescriber is willing to submit the prior authorization and document the required counseling. None of that is guaranteed by the existence of the program itself. The clinical evidence behind tirzepatide and semaglutide is well established for adults with obesity, but which drug fits your situation, and whether the Bridge program's temporary pricing is still available when you ask, are questions for your prescriber and your plan, not for a news story about one company's market share.